The leading Asia-Pacific biotech specialist CRO Novotech celebrates its 100th employee appointment at the Seoul, South Korea office.

The Seoul office’s growth is partly due to the current trend of biotech’s moving their studies from US and EU to the Asia-Pacific region to ensure continuity during the COVID-19 crisis.

In addition, South Korea is known globally for its medical research excellence, strong clinical research regulatory support from the Government, and access to diverse patient populations.

The South Korean team has completed 255 studies to date, with 184 currently active.

For the full article from Novotech, please click here.